Anticholinergic Medication Use, Dopaminergic Genotype, and Recurrent Falls.

ABSTRACT:

Background

Anticholinergic medications are associated with fall risk. Higher dopaminergic signaling may provide resilience to these effects. We tested interactions between anticholinergic medication use and dopaminergic genotype on risk for recurrent falls over 10 years.

Methods

Participants in the Health, Aging, and Body Composition (Health ABC) study (n = 2 372, mean age = 73.6; 47.8% men; 60.0% White) without disability or anticholinergic use at baseline were followed for up to 10 years for falls. Medication use was documented in 7 of 10 years. Highly anticholinergic medications were defined by Beers criteria, 2019. Recurrent falls were defined as ≥2 in the 12 months following medication assessment. Generalized estimating equations tested the association of anticholinergi

SUBMITTER: Rosso AL 

PROVIDER: S-EPMC9071487 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature